QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

OCUL

QT61Ocular Therapeutix, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
9.43
-0.21-2.18%
OverviewShort InterestFilings
OCULQT61Ocular Therapeutix, Inc.·NASDAQ
OverviewShort InterestFilings
9.43-2.18%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.46
Insider Own16.48%
Shs Outstand218.96M
Perf Week8.39%
Market Cap2.11BForward P/E-EPS next Y-1.45Insider Trans-0.08%Shs Float-Perf Month18.02%
Enterprise Value1.52BPEG0.32EPS next Q-0.40Inst Own-Short Float-Perf Quarter14.03%
Income-283899621.00P/S40.56EPS this Y-9.40%Inst Trans-Short Ratio-Perf Half Y-34.47%
Sales52.04MP/B3.71EPS next Y9.05%ROA-39.66%Short Interest-Perf YTD-22.32%
Book/sh2.66P/C-EPS next 5Y-ROE-64.55%52W High16.44 -42.64%Perf Year13.61%
Cash/sh3.05P/FCF-EPS past 3/5Y-ROIC-43.52%52W Low6.23 51.36%Perf 3Y-
Dividend Est.-EV/EBITDA-5.56Sales past 3/5Y0.65% 25.06%Gross Margin87.24%Volatility5.65% 4.01%Perf 5Y-
Dividend TTM-EV/Sales29.28EPS Y/Y TTM-19.67%Oper. Margin-575.42%ATR (14)0.54Perf 10Y-
Dividend Ex-Date-Quick Ratio14.73Sales Y/Y TTM-18.75%Profit Margin-558.24%RSI (14)58.57Recom2.00
Dividend Gr. 3/5Y-Current Ratio14.81EPS Q/Q-10.81%SMA208.33%Beta1.17Target Price30.00
Payout0.00%Debt/Eq0.14Sales Q/Q0.00%SMA504.53%Rel Volume2.08Prev Close9.64
Employees274LT Debt/Eq0.12EarningsAug 04SMA200-10.31%Avg Volume2.94MPrice9.43
IPO DateJul 25, 2014Option/ShortYes / YesEPS/Sales Surpr.-28.12% -15.38%Net Debt/EBITDA2.14Volume6,114,245Change-2.18%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-18-26ReiteratedRobert W. Baird$24 → $30
Feb-05-26ReiteratedRBC Capital$30
Dec-08-25ReiteratedH.C. WainwrightBuy$19 → $21
Oct-08-25ReiteratedH.C. WainwrightBuy$15 → $19
Oct-03-25ReiteratedRobert W. Baird$17 → $24
Oct-03-25ReiteratedPiper SandlerOverweight$15 → $31
Oct-01-25ReiteratedJMP SecuritiesMarket Outperform$19 → $29
Mar-04-25ReiteratedJMP SecuritiesMarket Outperform$24 → $19
Aug-08-24ReiteratedRobert W. Baird$18 → $17
Jun-27-24ReiteratedPiper SandlerOverweight$10 → $15
Latest News
Jun-18-26
Jun-18-2611:55AM
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25Benzinga
09:09AM
Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $30Benzinga
Jun-17-26
Jun-17-2611:42PM
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day TranscriptSeekingAlpha
11:33PM
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day - SlideshowSeekingAlpha
10:55AM
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug ProgramBenzinga
08:46AM
Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028Benzinga
Jun-12-26
Jun-12-2604:32PM
Ocular Therapeutix Appoints Jason Robins CFO, Effective June 10Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue525264
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A776
Gross Profit464558
Selling, General and Administrative Excl. Other125118102
Research and Development220197128
Other Operating Expense-100
Operating Income-300-270-172
Interest Expense121214
Unusual Expense
———
Non-Operating Income (Expense)-21-168
Net Income Before Taxes-291-266-194
Income Taxes000
Consolidated Net Income-291-266-194
Net Income From Continuing Operations-291-266-194
Net Income-291-266-194
EPS (Recurring)-1.46-1.42-1.22
EPS (Basic, Before Extraordinaries)-1.46-1.42-1.22
EPS (Diluted)-1.46-1.42-1.22
EBITDA-275-250-176
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio40.6243.66—
Gross Margin88.4686.5490.63
Operating Margin-576.92-519.23-268.75
Net Margin-559.62-511.54-303.13
Shares Outstanding224187158
Market Capitalization2,1122,270—
Operating Lease Expense
———
Insider Trading Volume
$11.23$9.67$8.10$6.53$4.97● Close Price0.00M0.44M0.88M1.32M1.75MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Waheed NadiaChief Medical OfficerJun 03 '26Sale8.2714,828122,628300,079Jun 05 12:00 AM
Heier Jeffrey S.Chief Scientific OfficerMay 26 '26Sale8.203,01824,748320,350May 28 12:00 AM
Dugel PravinSee RemarksMay 26 '26Sale8.2021,156173,4792,597,170May 28 12:00 AM
Kaiser PeterChief Development OfficerMay 26 '26Sale8.202,96724,329266,141May 28 12:00 AM
Nayak SanjayChief Strategy OfficerMay 26 '26Sale8.201,85815,236328,795May 28 12:00 AM
Dugel PravinSee RemarksFeb 23 '26Sale8.2820,056166,0643,013,022Feb 25 12:00 AM
Kaiser PeterChief Development OfficerFeb 23 '26Sale8.282,81023,267269,108Feb 25 12:00 AM
Heier Jeffrey S.Chief Scientific OfficerFeb 23 '26Sale8.283,05725,312323,368Feb 25 12:00 AM
Nayak SanjayChief Strategy OfficerFeb 23 '26Sale8.281,75914,565330,653Feb 25 12:00 AM
Waheed NadiaChief Medical OfficerFeb 20 '26Sale7.743,51027,167314,907Feb 24 12:00 AM
LINDSTROM RICHARD L MDDirectorFeb 20 '26Buy7.6660,229461,354246,933Feb 24 12:00 AM
Notman DonaldChief Operating OfficerFeb 12 '26Sale9.0411,446103,472366,356Feb 17 12:00 AM
Nayak SanjayChief Strategy OfficerFeb 12 '26Sale9.0410,34893,546332,412Feb 17 12:00 AM
Dugel PravinSee RemarksFeb 12 '26Sale9.04124,8821,128,9333,033,078Feb 17 12:00 AM
Waheed NadiaChief Medical OfficerFeb 12 '26Sale9.047,86371,082318,417Feb 17 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR